Please assess the completion status of the following clinical trial:

Trial Title: Study of Lamotrigine to Treat Ménière's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants aged 18 years or older~* Diagnosed with unilateral definite Ménière's disease according to the AAO-HNS 1995 criteria, confirmed by an ENT~* Active vertigo: at least two Ménière's vertigo attacks (defined as lasting 20 minutes or longer and associated with tinnitus, ear fullness, or low frequency hearing loss and nausea/vomiting) every four weeks during the eight-week qualification period and at least two more Ménière's vertigo attacks during the lead-in phase prior to randomization~* Documented unilateral lower frequency hearing loss defined as the four-tone average (arithmetic mean rounded to the nearest whole number) of the pure-tone thresholds at 0.25, 0.5, 1 and 2 kilohertz (kHz) more than or equal to 25 decibels (dB) of the worse audiogram during the six months before screening~* Have tried diuretics for at least one month and discontinued treatment due to continued vertigo attacks~* All other co-existing medical or psychiatric conditions are stable, and no greater than moderate severity~* Willing to avoid pregnancy during the entirety of the study (abstinence or two forms of acceptable birth control, such as condoms and oral contraceptives)~Exclusion Criteria:~* Bilateral Ménière's disease~* Current or past history of migraine~* Any other neuro-otologic disease or major vestibular abnormality found during screening that could confound the evaluation of Ménière's symptoms~* Previous intolerance or sensitivity to lamotrigine~* On any prohibited medication within four weeks prior to the study~* History of tympanostomy tubes with evidence of perforation or lack of closure~* IT gentamicin injections or endolymphatic sac surgery within the last year~* History of or current immunodeficiency disease, nephrolithiasis, hypertension, cardiac disease, arrhythmia, hypercholesterolemia, hemiplegic/basilar migraine, stroke, diabetes, vascular disease or kidney disease~* Family history of unexplained deafness~* Pregnant or breastfeeding~* Current diseases or conditions that may be associated with an altered perception of processing stimuli~* Current severe medical condition(s) that in the view of the investigator prohibits participation~* Previously used the investigational drug~* Current non-vertiginous dizziness (orthostatic or panic disorder) unless it could be clearly differentiated from Ménière's attacks by the participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): The placebo will match the lamotrigine dosage, frequency and duration.
- Lamotrigine (Type: ACTIVE_COMPARATOR): Lamotrigine will be taken orally for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Patients who withdraw at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.

Based on this trial design, predict the completion outcome and termination type (if applicable).